GSK-3β and FKHR phosphorylation following CCL25 treatment. Cells were tested for their ability to phosphorylate GSK-3β-Ser9 and FKHR-Thr24 following treatment with or without CCL25, cisplatin, wortmannin, and/or PF-573, 228. FACE assays quantified in situ total and phosphorylated protein levels before (0) or after (5 or 10 minutes) CCL25 stimulation in the presence of cisplatin and inhibitors. The ratio of phosphorylated:total GSK-3β or FKHR are presented ± SEM from 3 separate experiments performed in triplicate. Asterisks (*) indicated statistical differences (p < 0.01) between untreated and treated cells.